February 5, 2018

Contact: (703) 951-3814
info@pneumodose.com
 

PneumoDose Announces Partnership with Noble Life Sciences

Alexandria, VA – PneumoDose, LLC, a northern Virginia-based pharmaceutical technology company co-founded by Mark Bailey, Larry Bowen, Brett Haupt, and Matt Staymates, has partnered with Maryland-based Noble Life Sciences, Inc., to provide aerosol research services for Noble Life Science’s pharmaceutical customers.

There is considerable interest within the pharmaceutical industry to develop inhalational forms of various drugs, and not just drugs to treat diseases of the lungs.  However, preclinical testing of these types of drug formulations can be a cumbersome and expensive process, and current methods can generate significant statistical variation. PneumoDose’s unique expertise and aerosol technology allows pharmaceutical customers to precisely dose multiple animals at a time. This makes it easier for drug companies to generate high-quality preclinical data.

“PneumoDose is very excited to partner with Noble Life Sciences and to help them provide advanced aerosol capabilities to their customers," said PneumoDose Co-Founder Mark Bailey. “We are looking forward to a great relationship with Noble.”

The founders of PneumoDose first joined forces at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) in 2013, where they worked closely to develop better ways to deliver biological aerosols to support medical countermeasure development.

“Current methods of testing aerosol drugs in preclinical studies are time consuming, expensive, and imprecise,” Bailey continued, “PneumoDose strives to make it easier, faster, and less expensive for pharmaceutical companies to get their inhalational products out the door to the patients who need them.”

“PneumoDose’s unique expertise and technology can significantly reduce the time and investment required for our customers to generate high-quality data for GLP or non-GLP preclinical projects to support new inhalational drug or inhalational disease model development,” said Srujana Cherukuri, CEO of Noble Life Sciences. “We are very excited about our partnership with PneumoDose.”

About Noble Life Sciences, Inc.

Noble Life Sciences is a preclinical contract research organization (CRO) owned and operated by scientists with decades of experience in pharmaceutical development.  The company provides integrated GLP and non-GLP preclinical services designed to accelerate development for drugs, vaccines and medical devices.  Noble offers services in pharmacology, disease models, early safety assessments, toxicology, GLP custom polyclonal antibodies, cell line development, and analytical testing.

About PneumoDose, LLC

PneumoDose is a veteran-owned pharmaceutical technology company founded by a team of scientists and engineers with decades of combined experience in aerosol research.  The company focuses on bringing advanced aerosol capabilities to preclinical inhalational drug studies. PneumoDose’s unique expertise and technology can significantly reduce the time and investment required for pharmaceutical companies to generate high-quality, GLP or non-GLP, data sets to support new inhalational drug or inhalational disease model development.